IN THE CLAIMS:

Please enter the following new and amended claims:

1. (Amended) A method for suppressing viral growth in a host infected with a virus [which consists essentially of] comprising (a) providing a composition comprising a substantially purified compound; and (b) administering to the host an effective viral growth suppressing amount of [a composition consisting essentially of a compound of] the compound, wherein the compound is a derivative of nordihydroguaiaretic acid (NDGA) and has a formula:



wherein R_1, R_2, R_3 and R_4 are each selected from the group consisting of HO-, CH_3O- and $CH_3(C=O)O$-, or a water soluble substituent, provided that R_1, R_2, R_3 and R_4 are not each HO-, CH_3O- and $CH_3(C=O)O$-, simultaneously.

2. (Amended) The method of claim 1, wherein [said compound is] the water-soluble substituent is $-O-(C=O)-CH_2-N-(CH_3)_2 \cdot Cl$.

3. (Amended) The method of claim 1, wherein the host is infected with [for suppressing] Herpes simplex virus [in the host].

Please add the following new claims:

4. The method of claim 1, wherein the water-soluble substituent is $-O-(C=O)-CH_2-NH_2$.

5. The method of claim 1, wherein the substantially purified compound inhibited viral transcription.

6. The method of claim 1, wherein the substantially purified compound inhibited transactivation of viral gene.

7. The method of claim 1, wherein the compound is 1-(3,4-dihydroxyphenyl)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutane (4-O-methyl-NDGA).

8. The method of claim 1, wherein the compound is 1-(3,4-dihydroxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3-O-methyl-4-O-acetyl-NDGA).

9. The method of claim 1, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutane (3,3',4-tri-O-methyl-NDGA).

10. The method of claim 1, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutane (3,4,4'-tri-O-methyl-NDGA).

11. The method of claim 1, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3-acetoxy-4-methoxyphenyl)-2,3-dimethylbutane (3',4-di-O-methyl-3-O-acetyl-NDGA).

12. The method of claim 1, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3,3'-di-O-methyl-4-O-acetyl-NDGA).

13. The method of claim 1, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3-acetoxy-4-methoxyphenyl)-2,3-dimethylbutane (4,4'-di-O-methyl-3-O-acetyl-NDGA).

14. The method of claim 1, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3,4'-di-O-methyl-4-O-acetyl-NDGA).

15. A method of inhibiting replication of an acyclovir-resistant virus in a cell comprising the steps of:

(a) providing a substantially purified compound having a formula:



wherein R_1, R_2, R_3 and R_4 are each selected from the group consisting of HO-, CH_3O- and $CH_3(C=O)O$-, or a water soluble substituent; and

(b) contacting the cell with the substantially purified compound.

16. A method of treatment of acyclovir-resistant viral infection in a subject comprising the steps of:

(a) providing a substantially purified compound having a formula:



wherein R_1, R_2, R_3 and R_4 are each selected from the group consisting of HO-, CH_3O- and $CH_3(C=O)O$-, or a water soluble substituent; and

(b) administering the substantially purified compound to the subject.

17. A method of treatment of a subject infected with a virus, wherein the virus is susceptible to development of resistance to acyclovir comprising the steps of (a) providing a composition comprising a substantially purified compound; and (b) administering a therapeutically effective amount of the compound to the subject, wherein the compound is a derivative of NDGA.

18. The method of claim 17, wherein the compound has a formula:



wherein R_1, R_2, R_3 and R_4 are each selected from the group consisting of HO-, CH_3O- and $CH_3(C=O)O$-, or a water soluble substituent.

19. The method of claim 18, wherein the water-soluble substituent is $-O-(C=O)-CH_2-NH_2$.

20. The method of claim 18, wherein the water-soluble substituent is $-O-(C=O)-CH_2-N-(CH_3)_2 \cdot Cl$.

21 The method of claim 17, wherein the substantially purified compound inhibited viral transcription.

22. The method of claim 17, wherein the substantially purified compound inhibited transactivation of the viral gene.

23. The method of claim 18, wherein the compound is 1-(3,4-dihydroxyphenyl)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutane (4-O-methyl-NDGA).

24. The method of claim 18, wherein the compound is 1-(3,4-dihydroxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3-O-methyl-4-O-acetyl-NDGA).

25. The method of claim 18, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutane (3,3',4-tri-O-methyl-NDGA).

26. The method of claim 18, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutane (3,4,4'-tri-O-methyl-NDGA).

27. The method of claim 18, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3-acetoxy-4-methoxyphenyl)-2,3-dimethylbutane (3',4-di-O-methyl-3-O-acetyl-NDGA).

28. The method of claim 18, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3,3'-di-O-methyl-4-O-acetyl-NDGA).

29. The method of claim 18, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3-acetoxy-4-methoxyphenyl)-2,3-dimethylbutane (4,4'-di-O-methyl-3-O-acetyl-NDGA).

30. The method of claim 18, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3,4'-di-O-methyl-4-O-acetyl-NDGA).

31. A water-soluble derivative of NDGA.

32. The water-soluble derivative of NDGA as in claim 31, having the formula:



wherein R_1, R_2, R_3 and R_4 are each –O-(C=O)-CH_2-NH-$(CH_3)_2$.Cl.

33. The water-soluble derivative of NDGA as in claim 31, having the formula:



wherein R_1, R_2, R_3 and R_4 are each –O-(C=O)-CH_2-NH_2.

34. A composition comprising the water-soluble derivative of NDGA as in claim 31 and a carrier.

35. The composition of claim 34 wherein the carrier is 10% DMSO in calcium-magnesium-free PBS.

36. A derivative of NDGA having a formula:



wherein R_1, and R_2 together form a cyclic substituent and R_3 and R_4 together form a cyclic substituent.

37. The derivative of NDGA as in claim 36, wherein the derivative has a formula:



38. The derivative of NDGA as in claim 36, wherein the derivative has a formula:



39. A method of treatment of viral infection in a host comprising the steps of: (a) providing a composition comprising a compound; and (b) administering a viral inhibitory amount of the compound to the host, wherein the compound has the formula selected from the group consisting of:



and



Status of Claims

Claims 1-3 were issued, and are sought to be amended. Claims 4-39 are sought to be added. Upon entry of this amendment, claims 1-39 will be pending.

Support for Patent Changes

Amendment to the specification is made to correct minor errors in spelling the names of the compounds and other minor errors of a clerical nature. Support can be found, for example, in the structural formulae that represent the compounds.

Support for amended claim 1 can be found, for example, at col. 2, lines 13-16 and at col. 3, lines 28-30 of the patent. Support for amended claim 2 can be found, for example, at col. 15, lines 58-65 of the patent. Support for amended claim 3 can be found, for example, at col. 2, lines 13-16, of the patent. Support for new claim 4 can be found, for example, at col. 16, lines 1-5 of the patent. Support for new claims 5 and 6 can be found, for example, at col. 16, lines 44-48 of the patent. Support for new claim 7 can be found, for example, at col. 11, line 55 of the patent. Support for new claim 8 can be found, for example, at col. 11, line 40 of the patent. Support for new claim 9 can be found, for example, at col. 12, line 20 of the patent. Support for new claim 10 can be found, for example, at col. 12, line 35 of the patent. Support for new claim 11 can be found, for example, at col. 12, line 55 of the patent. Support for new claim 12 can be found, for example, at col. 13, line 5 of the patent. Support for new claim 13 can be found, for example, at col. 13, line 20 of the patent. Support for new claim 14 can be found, for example, at col. 13, line 35 of the patent.

Support for new claims 15-17 can be found, for example, in col. 18, in Table 5 of the patent. Support for new claim 18 can be found at col. 11, line 55 of the patent. Support for new claim 19 can be found, for example, at col. 16, lines 1-5 of the patent. Support for new claim 20 can be found, for example, at col. 15, lines 58-65 of the patent. Support for new claims 21-22 can be found, for example, at col. 16, lines 44-48 of the patent. Support for new claim 23 can be found, for example, at col. 11, line 55 of the patent. Support for new claim 24 can be found, for example, at col. 11, line 40 of the patent. Support for new claim 25 can be found, for example, at col. 12, line 20 of the patent. Support for new claim 26 can be found, for example, at col. 12, line 35 of the patent. Support for new claim 27 can be found, for example, at col. 12, line 55 of the patent. Support for new claim 28 can be found, for example, at col. 13, line 5 of the patent. Support for new claim 29 can be found, for example, at col. 13, line 20 of the

patent. Support for new claim 30 can be found, for example, at col. 13, line 35 of the patent.

Support for new claim 31 can be found, for example, at col. 15, line 55 to col. 16, line 5 of the patent. Support for new claim 32 can be found, for example, at col. 15 lines 44-65 of the patent. Support for new claim 33 can be found, for example, at col. 16, line 5 of the patent. Support for new claims 34 and 35 can be found, for example, at col. 14, lines 42-45 of the patent.

Support for new claims 36-39 can be found, for example, at col. 16, lines 7-25 of the patent. Support for new claim 39 can be found, for example, at col. 16, lines 10-24 of the patent.

Respectfully submitted,

9/17/03
Date

Ann S. Hobbs, Ph.D.
Registration No. 36,830
VENABLE
P.O. Box 34385
Washington, D.C. 20043-9998
Telephone: (202) 962-4800
Telefax: (202) 962-8300